Moreover, an increased proportion of CD163+ monocytes has been described in different ARDs such as type 2 diabetes [12] and cancer [13], lending further support to the hypothesis that healthy aging could be associated with a reduced proportion of M2-monocytes. Here, CD163 is linked to cancer.